Hikma Pharmaceuticals Plc Hikma announces agreement with Vectura
November 22 2016 - 2:02AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
22 November 2016
Hikma announces agreement with Vectura for the development of
generic salmeterol for the US market
London, 22 November 2016 - Hikma Pharmaceuticals PLC (Hikma)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's /
BB+ S&P, both stable), the fast growing multinational
pharmaceutical group, announces that its wholly owned US affiliate,
West-Ward Pharmaceuticals Corp. (West-Ward), has signed a
development and licensing agreement with Vectura for its generic
salmeterol product (VR730). Generic salmeterol is a generic long
acting beta-agonists (LABA) for the treatment of asthma and COPD,
delivered using Vectura's proprietary dry powder inhalation
technology and device. According to IMS Health, US sales of inhaled
DPI and pMDI LABAs were approximately $150 million in 2015.
Under the terms of this agreement, Hikma will be responsible for
the clinical development, manufacture and commercialisation of the
product. Vectura will complete the formulation development of
generic salmeterol, which will largely be funded by Hikma. Vectura
will receive an initial payment of $375,000 and potential further
development, filing, approval and launch milestones up to an
aggregate amount of $1.125 million. Vectura is also eligible for a
share of future returns of the product, subject to certain
recoveries by Hikma for the costs of the clinical endpoint pivotal
trial.
Mike Raya, Chief Executive Officer of West-Ward Pharmaceuticals
said, "We are very pleased to be extending our partnership with
Vectura. This builds on the strong relationship we have established
through our programme for the development of generic Advair
Diskus.(R) By leveraging Hikma's strong R&D, high-quality
manufacturing and excellent commercial capabilities, we are
successfully executing our pipeline development strategy for our US
generics business and improving patient access to high quality,
affordable medicines."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44
(0)20 7399 2760/ +44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations +44 (0)20
7399 2765/ +44 7818 060211
West-Ward Pharmaceuticals
Keri Butler, US Public Affairs and Communications +1 614 272
4774/ +1 614 214 6657
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Injectables", "Branded"
and "Generics", based principally in the United States, the Middle
East and North Africa (MENA) and Europe. In the United States,
Hikma operates through its wholly owned subsidiary, West-Ward
Pharmaceuticals Corp., with operations based in New Jersey, Ohio
and Tennessee.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGGGWGUPQPPG
(END) Dow Jones Newswires
November 22, 2016 02:02 ET (07:02 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024